Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
1.
Nutrients ; 16(16)2024 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-39203927

RESUMEN

Many health-promoting effects have been attributed to the intake of probiotic cells. However, it is important that probiotic cells arrive at the site of their activity in a viable state in order to exert their beneficial effects. Careful selection of the appropriate probiotic formulation is therefore required as mainly the type of probiotic species/strain and the administration strategy may affect survival of the probiotic cells during the upper gastrointestinal (GIT) passage. Therefore, the current study implemented Simulator of the Human Microbial Ecosystem (SHIME®) technology to investigate the efficacy of different commercially available probiotic formulations on the survival and culturability of probiotic bacteria during upper GIT passage. Moreover, Colon-on-a-Plate (CoaP™) technology was applied to assess the effect of the surviving probiotic bacteria on the gut microbial community (activity and composition) of three human donors. Significantly greater survival and culturability rates were reported for the delayed-release capsule formulation (>50%) as compared to the powder, liquid, and standard capsule formulations (<1%) (p < 0.05), indicating that the delayed-release capsule was most efficacious in delivering live bacteria cells. Indeed, administration of the delayed-release capsule probiotic digest resulted in enhanced production of SCFAs and shifted gut microbial community composition towards beneficial bacterial species. These results thus indicate that careful selection of the appropriate probiotic formulation and administration strategy is crucial to deliver probiotic cells in a viable state at the site of their activity (distal ileum and colon).


Asunto(s)
Colon , Microbioma Gastrointestinal , Probióticos , Tracto Gastrointestinal Superior , Humanos , Colon/microbiología , Tracto Gastrointestinal Superior/microbiología , Viabilidad Microbiana , Bacterias/crecimiento & desarrollo , Ácidos Grasos Volátiles/metabolismo
2.
Int J Cancer ; 155(7): 1203-1211, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-38712628

RESUMEN

The relationship between Helicobacter pylori (H. pylori) infection and upper gastrointestinal (UGI) cancers is complex. This multicenter, population-based cohort study conducted in seven areas in China aimed to assess the correlation between current H. pylori infection and the severity of UGI lesions, as well as its association with the risk of gastric cancer (GC) and esophageal cancer (EC). From 2015 to 2017, 27,085 participants (aged 40-69) completed a standardized questionnaire, and underwent a 13C-urea breath test. Then a subset underwent UGI endoscopy to assess the UGI lesion detection rates. All individuals were followed up until December 2021 to calculate the hazard ratios (HRs) for UGI cancers. H. pylori infection prevalence was 45.9%, and among endoscopy participants, 22.2% had gastric lesions, 19.2% had esophageal lesions. Higher detection rates of gastric lesions were noted in the H. pylori-positive population across all lesion severity levels. Over a median follow-up of 6.3 years, 104 EC and 179 GC cases were observed, including 103 non-cardia gastric cancer (NCGC) cases and 76 cardia gastric cancer (CGC) cases. H. pylori-infected individuals exhibited a 1.78-fold increased risk of GC (HR 1.78, 95% confidence interval [CI] 1.32-2.40) but no significant increase in EC risk (HR 1.07, 95% CI 0.73-1.57). Notably, there was a higher risk for both NCGC and CGC in H. pylori-infected individuals. This population-based cohort study provides valuable evidence supporting the association between current H. pylori infection and the risk of both NCGC and CGC. These findings contribute to the empirical basis for risk stratification and recommendations for UGI cancer screening.


Asunto(s)
Neoplasias Esofágicas , Infecciones por Helicobacter , Helicobacter pylori , Neoplasias Gástricas , Humanos , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Persona de Mediana Edad , Masculino , Femenino , Helicobacter pylori/aislamiento & purificación , Adulto , Neoplasias Gástricas/microbiología , Neoplasias Gástricas/epidemiología , Neoplasias Gástricas/etiología , Neoplasias Gástricas/patología , Anciano , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/microbiología , Neoplasias Esofágicas/etiología , China/epidemiología , Estudios de Cohortes , Factores de Riesgo , Prevalencia , Neoplasias Gastrointestinales/microbiología , Neoplasias Gastrointestinales/epidemiología , Neoplasias Gastrointestinales/etiología , Tracto Gastrointestinal Superior/patología , Tracto Gastrointestinal Superior/microbiología
3.
J Clin Rheumatol ; 27(1): 40-41, 2021 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-33347033

RESUMEN

BACKGROUND/AIMS: A role for Helicobacter pylori in triggering systemic sclerosis (SSc) has been proposed, but data are conflicting. In previous studies, infection has been generally searched for by using serology. We designed this study to assess H. pylori prevalence in SSc patients with histology of gastric mucosa, considered the criterion standard for infection diagnosis. METHODS: This cross-sectional study enrolled 30 SSc patients who complained of upper gastrointestinal symptoms. All underwent upper endoscopy with gastric biopsies. Endoscopic alterations were recorded, and gastric mucosa biopsies were used for both histological examination and searching for H. pylori. The role for proton-pump inhibitor (PPI) therapy was considered. Fisher exact test was used for statistical analysis. RESULTS: Data of 28 SSc patients were available, 14 with ongoing PPI therapy. Helicobacter pylori infection at histology was detected in 14.3% patients, and it equally occurred in patients with or without PPI therapy. Erosive esophagitis/Barrett esophagus was detected in 26.6% of cases. Among patients with PPI therapy, 30% received half dose only. The prevalence of intestinal metaplasia was low (14.3%). Endoscopic esophageal alterations were significantly more frequent in those patients showing anti-Scl70 antibody positivity. CONCLUSIONS: This study showed that prevalence of H. pylori is very low in SSc patients, so that it seems not having a role in triggering SSc. Management of gastroesophageal diseases in SSc patients needs to be improved, and looking to the autoimmune profile may be of help. Thus, collaboration between rheumatologist and gastroenterologist is highly recommended.


Asunto(s)
Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Proteínas Nucleares/inmunología , Inhibidores de la Bomba de Protones/uso terapéutico , Esclerodermia Sistémica , Tracto Gastrointestinal Superior , Autoanticuerpos/sangre , Esófago de Barrett/patología , Biopsia/métodos , ADN-Topoisomerasas de Tipo I , Endoscopía del Sistema Digestivo/métodos , Femenino , Mucosa Gástrica/microbiología , Mucosa Gástrica/patología , Reflujo Gastroesofágico/tratamiento farmacológico , Infecciones por Helicobacter/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Medición de Riesgo , Esclerodermia Sistémica/sangre , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/microbiología , Esclerodermia Sistémica/fisiopatología , Tracto Gastrointestinal Superior/diagnóstico por imagen , Tracto Gastrointestinal Superior/microbiología , Tracto Gastrointestinal Superior/patología
4.
Digestion ; 101(1): 38-45, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31752012

RESUMEN

BACKGROUND: Functional dyspepsia (FD) is associated with poor health-related quality of life. Recent evidence suggests that the main pathogenesis suspect is the gut mucosa-associated microbiota (MAM). However, little is known about the MAM in FD subjects. The aim of this study was to clarify the relationship between upper gastrointestinal symptoms in FD and the characteristics of the gastrointestinal MAM. SUMMARY: Five mucosa samples from the upper gut (intraoral, mid-esophagus, gastric body, gastric antrum, and descending portion of the duodenum) were collected with a brush under endoscopic examination from FD and healthy control subjects. MAM profiles of each sample were analyzed by 16S-rRNA -V3-V4 gene sequences. Questionnaire was used to assess gastrointestinal symptoms in FD. Between FD and healthy control subjects, although the comparison of MAM α-diversity showed no significant differences, the structure of MAM (ß-diversity) was clearly different. Only the phylum Firmicutes was increased in FD compared to healthy control subjects in all sites of the upper gut. At the genus level, Streptococcus was significantly increased in all sites in the upper gut in FD. The relative abundance of Streptococcus was positively correlated with upper gastrointestinal symptoms in each upper gut group. Furthermore, the relative abundance of OTU 90 was positively correlated with upper gastrointestinal symptoms in all sites in the upper gut in FD. Key Messages: Streptococcus is a bacterium strongly correlated with upper gastrointestinal symptoms in FD.


Asunto(s)
Dispepsia/microbiología , Microbioma Gastrointestinal , Membrana Mucosa/microbiología , Infecciones Estreptocócicas/complicaciones , Tracto Gastrointestinal Superior/microbiología , Adulto , Anciano , ADN Bacteriano/aislamiento & purificación , Dispepsia/complicaciones , Femenino , Firmicutes/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Infecciones Estreptocócicas/microbiología , Streptococcus/aislamiento & purificación
5.
PLoS One ; 14(4): e0214859, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31002668

RESUMEN

In developing an oral bait BCG vaccine against tuberculosis in badgers we wanted to understand the conditions of the gastrointestinal tract and their impact on vaccine viability. Conditions mimicking stomach and small-intestine caused substantial reduction in BCG viability. We performed in vivo experiments using a telemetric pH monitoring system and used the data to parameterise a dynamic in vitro system (TIM-1) of the stomach and small intestine. Some BCG died in the stomach compartment and through the duodenum and jejunum compartments. BCG survival in the stomach was greatest when bait was absent but by the time BCG reached the jejunum, BCG viability was not significantly affected by the presence of bait. Our data suggest that from a starting quantity of 2.85 ± 0.45 x 108 colony-forming units of BCG around 2 log10 may be killed before delivery to the intestinal lymphoid tissue. There are economic arguments for reducing the dose of BCG to vaccinate badgers orally. Our findings imply this could be achieved if we can protect BCG from the harsh environment of the stomach and duodenum. TIM-1 is a valuable, non-animal model with which to evaluate and optimise formulations to maximise BCG survival in the gastrointestinal tract.


Asunto(s)
Vacuna BCG/administración & dosificación , Vacuna BCG/inmunología , Mustelidae/inmunología , Mustelidae/microbiología , Mycobacterium bovis/inmunología , Vacunación/veterinaria , Administración Oral , Animales , Carga Bacteriana , Reservorios de Enfermedades/microbiología , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Viabilidad Microbiana/inmunología , Modelos Biológicos , Tuberculosis/inmunología , Tuberculosis/prevención & control , Tuberculosis/veterinaria , Tracto Gastrointestinal Superior/inmunología , Tracto Gastrointestinal Superior/metabolismo , Tracto Gastrointestinal Superior/microbiología , Vacunación/métodos
6.
Benef Microbes ; 10(1): 77-87, 2019 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-30694101

RESUMEN

The aim of this study was to assess the germination, survival and metabolic activity of the probiotic Bacillus coagulans GBI-30, 6086 [GanedenBC30] (BC30) in a dynamic, computer controlled in vitro model of the gastrointestinal (GI) tract, simulating human adults. Experiments were performed in the presence of a meal to maximise germination, due to the presence of germination-triggers. Both an upper GI tract (stomach and small intestine; TIM-1) and a colon model (TIM-2) were used, where material exiting TIM-1 was added to TIM-2. Spores of BC30 were introduced in the gastric compartment of TIM-1 and samples were taken immediately after the pylorus. Moreover, for 6 h, every hour the ileal efflux was collected and a subsample was plated for viable counts (spores and germinated cells). The remainder of the sample was fed to TIM-2, and after 24 h another sample was taken and tested for viable counts. In addition, samples were taken from the dialysates of the model and analysed using LC-MS/MS to determine bacterial metabolites and digestion products. Survival after transit through the gastric compartment was high (97%) and most cells were still in the spore form (76%). Survival after transit through TIM-1 was on average 51%, meaning that on average half of the orally provided spores was found back as cfu on the agar plates. Of these on average 93% were germinated cells and only 7% were spores. 24 h after the start of the experiments germination had increased in TIM-2 to 97% vegetative cells, and only 3% spores. No further loss of viability was observed in TIM-2. In terms of metabolic activity, increased levels of amino acids, dipeptides and citric acid cycle metabolites were found compared to experiments in the absence of BC30. In conclusion, BC30 spores germinate to a large extent (>90%) in the presence of germination triggers in the small intestine in a model that closely mimics the physiological conditions of human adults. Of the oral dose, as much as half of the cells survived transit through the upper GI tract, and based on the metabolite profile, these cells were metabolically active. Either these cells or the enzymes released from the dead cells aided in digestion of the meal. These insights help explain some of the observations in previous experiments, and support the understanding of the mechanism of action of the probiotic BC30.


Asunto(s)
Bacillus coagulans/fisiología , Simulación por Computador , Tracto Gastrointestinal/microbiología , Modelos Biológicos , Probióticos , Bacillus coagulans/enzimología , Bacillus coagulans/crecimiento & desarrollo , Colon/microbiología , Tracto Gastrointestinal/metabolismo , Humanos , Técnicas In Vitro , Comidas , Viabilidad Microbiana , Esporas Bacterianas/crecimiento & desarrollo , Esporas Bacterianas/metabolismo , Esporas Bacterianas/fisiología , Tracto Gastrointestinal Superior/metabolismo , Tracto Gastrointestinal Superior/microbiología
7.
J Agric Food Chem ; 66(47): 12580-12593, 2018 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-30406656

RESUMEN

Although in vitro studies to identify interactions between food components and the colonic microbiota employ distinct methods to mimic upper gastrointestinal (GI) tract digestion, the effects of differences in protocols on fermentation have not been rigorously addressed. Here, we compared two widely used upper GI tract digestion methods on four different cereal brans in fermentations by fecal microbiota to test the hypotheses that (1) different methods are varyingly efficient in removing accessible starches and proteins from dietary components and (2) these result in cereal-specific differences in fermentation by fecal microbiota. Our results supported both hypotheses, in that the methods differed significantly in bran starch and protein retention and that the effects were cereal-specific. Furthermore, these differences impacted fermentation by the fecal microbiota of healthy donors, altering both short-chain fatty acid production and microbial community composition. These data suggest that digestion methods should be standardized across laboratories for in vitro fiber fermentation studies.


Asunto(s)
Fibras de la Dieta/metabolismo , Grano Comestible/metabolismo , Heces/microbiología , Microbioma Gastrointestinal , Tracto Gastrointestinal Superior/microbiología , Adulto , Bacterias/clasificación , Bacterias/genética , Bacterias/aislamiento & purificación , Bacterias/metabolismo , Digestión , Grano Comestible/clasificación , Ácidos Grasos Volátiles/metabolismo , Femenino , Fermentación , Humanos , Masculino , Modelos Biológicos , Tracto Gastrointestinal Superior/metabolismo
8.
Food Funct ; 9(11): 5868-5879, 2018 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-30362482

RESUMEN

Akkermansia muciniphila, an abundant member of the human gut microbiota, has been suggested as a potential next-generation probiotic. However, its high sensitivity to oxygen limits the development of dosage protocols. Here, we describe microencapsulation, in a xanthan and gellan gum matrix, and a subsequent freeze-drying protocol for A. muciniphila DSM22959. For comparison Lactobacillus plantarum subsp. plantarum ATCC14917 was microencapsulated and freeze-dried using similar protocols. Four different mixtures were tested for cryoprotective properties: sucrose 5% plus trehalose 5%; agave syrup 10%; skim milk 10%, glucose 1%, yeast extract 0.5%, and mannitol 2.5%; as well as peptone 0.1% plus sorbitol 1.2%. Milli-Q-water served as control. Only cryoprotectant solutions with high sugar or protein content significantly improved the survival of both strains during freeze-drying. Microencapsulated cells were stored aerobically or anaerobically for 1 month at 4 °C or 25 °C. Survival of A. muciniphila was significantly better when stored anaerobically at 4 °C. The survival of microencapsulated L. plantarum, was relatively stable at both temperatures under anaerobic conditions. Survival of microencapsulated cells was compared with that of free cells during in vitro simulated upper gastrointestinal tract (GIT) transit at fasted and fed state. During in vitro simulated stomach passage, encapsulation significantly improved survival and viable cells remained at relevant levels after the entire simulated upper GIT transit. In conclusion, we here report a protocol for encapsulating A. muciniphila giving acceptable storage stability and enhancing survival during in vitro simulated upper GIT transit and thus constitutes an important step towards enabling future use of this important member of the human colonic microbiota as a probiotic.


Asunto(s)
Liofilización , Lactobacillus plantarum/crecimiento & desarrollo , Viabilidad Microbiana , Probióticos , Verrucomicrobia/crecimiento & desarrollo , Polisacáridos Bacterianos/química , Tracto Gastrointestinal Superior/metabolismo , Tracto Gastrointestinal Superior/microbiología
9.
Helicobacter ; 23 Suppl 1: e12522, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30203583

RESUMEN

The review of the most important recent publications concerning the relation of Helicobacter pylori with peptic ulcer disease (PUD), noninvestigated and functional dyspepsia, and gastroesophageal reflux disease (GERD) is presented. H. pylori remains the main etiopathogenetic factor in complicated and uncomplicated PUD. Nevertheless, the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin is increasing. The novel data did not confirm that PUD caused by NSAIDs and aspirin is less symptomatic. The role of glucocorticoids, immunosuppressants, and antidepressants seems to be of some importance. Although the involvement of H. pylori in functional dyspepsia is controversial, several data support the importance of H. pylori-induced gastritis in the pathogenesis of dyspeptic symptoms. Recent interventional studies have reported that H. pylori eradication improves dyspepsia mainly in areas with a high prevalence of this bacterium. Novel data regarding the relation of gastrointestinal peptides, ghrelin and obestatin, with H. pylori infection are also presented. Intriguing findings support the involvement of the gastric microbiota in the causation of chronic functional dyspepsia. Finally, some data concerning negative, positive, or neutral associations of H. pylori with gastroesophageal reflux disease (GERD) were published. In this context, today there is no evidence indicating that H. pylori eradication could worsen the symptoms or the course of GERD.


Asunto(s)
Enfermedades Gastrointestinales/microbiología , Infecciones por Helicobacter/microbiología , Helicobacter pylori/patogenicidad , Tracto Gastrointestinal Superior/microbiología , Animales , Humanos , Úlcera Péptica/microbiología , Úlcera Péptica/patología , Tracto Gastrointestinal Superior/patología
10.
J Appl Microbiol ; 124(6): 1604-1609, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29473976

RESUMEN

AIM: To test the effect of microencapsulation on the survival of two probiotic strains isolated from Dadih, Indonesian fermented buffalo milk, in a dynamic, computer-controlled in vitro model of the upper gastrointestinal (GI) tract (TIM-1), simulating human adults. METHODS AND RESULTS: Free or microencapsulated probiotics, Lactobacillus plantarum IS-10506 or Enterococcus faecium IS-27526, resuspended in milk were studied for survival in the complete TIM-1 system (stomach + small intestine) or in the gastric compartment of TIM-1 only. Hourly samples collected after the ileal-caecal valve or after the pylorus were plated on MRS agar (for Lactobacillus) or S&B agar (for Enterococcus). Survival of the free cells after transit through the complete TIM-1 system was on average for the E. faecium and L. plantarum 15·0 and 18·5% respectively. Survival of the microencapsulated E. faecium and L. plantarum was 15·7 and 84·5% respectively. The free cells were further assessed in only the gastric compartment of TIM-1. E. faecium and L. plantarum showed an average survival of 39 and 32%, respectively, after gastric passage. CONCLUSION: There is similar sensitivity to gastric acid as well as survival after complete upper GI tract transit of free cells, but microencapsulation only protected L. plantarum. SIGNIFICANCE AND IMPACT OF STUDY: Survival of microencapsulated L. plantarum IS-10506 is increased compared to free cells in a validated in vitro model of the upper GI tract. It increases its use as an ingredient of functional foods.


Asunto(s)
Composición de Medicamentos/métodos , Enterococcus faecium/fisiología , Lactobacillus plantarum/fisiología , Modelos Biológicos , Probióticos/química , Animales , Humanos , Leche , Tracto Gastrointestinal Superior/microbiología
11.
Lancet Gastroenterol Hepatol ; 2(4): 298-312, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28404159

RESUMEN

The distinctive anatomy and physiology of the upper gastrointestinal tract and the difficulty of obtaining samples led to the theory that it was bacteria free. However, multiomics studies are indicating otherwise. Although influenced by both oral and gastric bacteria, the resident microbial ecosystem in the oesophagus is dominated by Streptococcus. A shift from Gram-positive to Gram-negative bacteria occurs in oesophagitis and Barrett's oesophagus, and this shift might be involved in the pathogenesis of oesophageal adenocarcinoma. The gastric microenvironment is populated by microbial communities mainly of the Firmicutes, Actinobacteria, Bacteroidetes, and Proteobacteria phyla and species of the Lactobacillus, Streptococcus, and Propionibacterium genera. The composition of gastric microbiota is highly dynamic, and is influenced by acid suppression, gastric inflammation, and Helicobacter pylori. Duodenal microbes are also implicated in the onset and outcome of coeliac disease. Bacteria of the genera Bacteroides, Clostridium, and Staphylococcus dominate the duodenal flora in active coeliac disease whereas lactobacilli and bifidobacteria decrease. Although knowledge of the composition of the microbiota of the upper gastrointestinal tract has advanced substantially, this information is far from being translated to the clinical setting. In this Review, we assess the data related to the potential contribution of microbes to the susceptibility for and pathogenesis of upper gastrointestinal diseases.


Asunto(s)
Enfermedades Gastrointestinales/microbiología , Microbioma Gastrointestinal , Tracto Gastrointestinal Superior/microbiología , Enfermedad Celíaca/microbiología , Enfermedades del Esófago/microbiología , Predisposición Genética a la Enfermedad , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori , Humanos , Neoplasias Gástricas/microbiología
12.
J Clin Gastroenterol ; 51(2): 145-150, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26974758

RESUMEN

GOALS: The aim of this study was to compare upper gastrointestinal (UGI) versus lower gastrointestinal (LGI) delivery routes of fecal microbiota transplantation (FMT) for refractory or recurrent/relapsing Clostridium difficile infection (CDI). BACKGROUND: FMT has been proven to be a safe and highly effective therapeutic option for CDI. Delivery, however, could be via the UGI or LGI routes, and it is unclear as to which route provides better clinical outcome. STUDY: A systematic search for studies that reported the use of FMT for CDI treatment was conducted. Individual patient data that included demographic (age and sex) and clinical (route of FMT delivery, CDI outcome after FMT, and follow-up time) information were obtained. Kaplan-Meier cumulative hazard curves and Cox proportional hazard models were used to assess clinical failure after FMT by the route of delivery. RESULTS: Data from 305 patients treated with FMT (208 via LGI route and 97 via UGI route) for CDI were analyzed. At 30 and 90 days, the risk of clinical failure was 5.6% and 17.9% in the UGI group compared with 4.9% and 8.5% in the LGI delivery route group, respectively. A time-varying analysis suggested a 3-fold increase in hazard of clinical failure for UGI delivery (hazard ratio, 3.43; 95% confidence interval, 1.32-8.93) in the period after 30 days. CONCLUSIONS: FMT delivered via the LGI seems to be the most effective route for the prevention of recurrence/relapse of CDI. A randomized controlled trial is necessary to confirm whether FMT delivered via the LGI is indeed superior to that delivered via the UGI route.


Asunto(s)
Clostridioides difficile , Enterocolitis Seudomembranosa/terapia , Trasplante de Microbiota Fecal/métodos , Tracto Gastrointestinal Inferior/microbiología , Tracto Gastrointestinal Superior/microbiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Enterocolitis Seudomembranosa/microbiología , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Recurrencia , Resultado del Tratamiento , Adulto Joven
13.
PLoS One ; 11(3): e0150519, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26930491

RESUMEN

Biliary bacteria have been implicated in gallstone pathogenesis, though a clear understanding of their composition and source is lacking. Moreover, the effects of the biliary environment, which is known to be generally hostile to most bacteria, on biliary bacteria are unclear. Here, we investigated the bacterial communities of the biliary tract, duodenum, stomach, and oral cavity from six gallstone patients by using 16S rRNA amplicon sequencing. We found that all observed biliary bacteria were detectable in the upper digestive tract. The biliary microbiota had a comparatively higher similarity with the duodenal microbiota, versus those of the other regions, but with a reduced diversity. Although the majority of identified bacteria were greatly diminished in bile samples, three Enterobacteriaceae genera (Escherichia, Klebsiella, and an unclassified genus) and Pyramidobacter were abundant in bile. Predictive functional analysis indicated enhanced abilities of environmental information processing and cell motility of biliary bacteria. Our study provides evidence for the potential source of biliary bacteria, and illustrates the influence of the biliary system on biliary bacterial communities.


Asunto(s)
Bilis/microbiología , Sistema Biliar/microbiología , Microbioma Gastrointestinal/fisiología , Tracto Gastrointestinal Superior/microbiología , Anciano , Secuencia de Bases , Duodeno/microbiología , Enterobacteriaceae/genética , Femenino , Cálculos Biliares/microbiología , Microbioma Gastrointestinal/genética , Humanos , Masculino , Datos de Secuencia Molecular , Boca/microbiología , ARN Ribosómico 16S/genética , Estómago/microbiología
14.
Food Microbiol ; 53(Pt A): 18-29, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26611166

RESUMEN

Streptococcus thermophilus, a lactic acid bacterium used to produce yogurts and cheeses is more and more considered for its potential probiotic properties. This implies that additional information should be obtained regarding its survival and metabolic activity in the human Gastro-Intestinal Tract (GIT). In this study, we screened 30 S. thermophilus strains for urease, small heat shock protein, and amino-acid decarboxylase functions which may play a role in survival in the upper part of the GIT. The survival kinetics of 4 strains was investigated using the TIM, a physiologically relevant in vitro dynamic gastric and small intestinal model. The three strains LMD9, PB18O and EBLST20 showed significantly higher survival than CNRZ21 in all digestive compartments of the TIM, which may be related to the presence of urease and heat shock protein functions. When LMD9 bacterial cells were delivered in a fermented milk formula, a significant improvement of survival in the TIM was observed compared to non-fermented milk. With the RIVET (Recombinase In Vivo Expression Technology) method applied to the LMD9 strain, a promoter located upstream of hisS, responsible for the histidyl-transfer RNA synthesis, was found to be specifically activated in the artificial stomach. The data generated on S. thermophilus survival and its adaptation capacities to the digestive tract are essential to establish a list of biomarkers useful for the selection of probiotic strains.


Asunto(s)
Viabilidad Microbiana , Streptococcus thermophilus/fisiología , Tracto Gastrointestinal Superior/metabolismo , Tracto Gastrointestinal Superior/microbiología , Yogur/microbiología , Adaptación Fisiológica , Animales , Digestión , Ácido Gástrico/metabolismo , Genes Bacterianos , Humanos , Leche/microbiología , Modelos Anatómicos , Probióticos/metabolismo , Streptococcus thermophilus/genética , Streptococcus thermophilus/metabolismo , Ureasa/metabolismo
15.
PLoS One ; 10(6): e0129055, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26076489

RESUMEN

BACKGROUND: The incidence of esophageal adenocarcinoma (EAC) has increased nearly five-fold over the last four decades in the United States. Barrett's esophagus, the replacement of the normal squamous epithelial lining with a mucus-secreting columnar epithelium, is the only known precursor to EAC. Like other parts of the gastrointestinal (GI) tract, the esophagus hosts a variety of bacteria and comparisons among published studies suggest bacterial communities in the stomach and esophagus differ. Chronic infection with Helicobacter pylori in the stomach has been inversely associated with development of EAC, but the mechanisms underlying this association remain unclear. METHODOLOGY: The bacterial composition in the upper GI tract was characterized in a subset of participants (n=12) of the Seattle Barrett's Esophagus Research cohort using broad-range 16S PCR and pyrosequencing of biopsy and brush samples collected from squamous esophagus, Barrett's esophagus, stomach corpus and stomach antrum. Three of the individuals were sampled at two separate time points. Prevalence of H. pylori infection and subsequent development of aneuploidy (n=339) and EAC (n=433) was examined in a larger subset of this cohort. RESULTS/SIGNIFICANCE: Within individuals, bacterial communities of the stomach and esophagus showed overlapping community membership. Despite closer proximity, the stomach antrum and corpus communities were less similar than the antrum and esophageal samples. Re-sampling of study participants revealed similar upper GI community membership in two of three cases. In this Barrett's esophagus cohort, Streptococcus and Prevotella species dominate the upper GI and the ratio of these two species is associated with waist-to-hip ratio and hiatal hernia length, two known EAC risk factors in Barrett's esophagus. H. pylori-positive individuals had a significantly decreased incidence of aneuploidy and a non-significant trend toward lower incidence of EAC.


Asunto(s)
Bacterias , Esófago de Barrett/genética , Esófago de Barrett/microbiología , Inestabilidad Genómica , Microbiota , Tracto Gastrointestinal Superior/microbiología , Adenocarcinoma/epidemiología , Adenocarcinoma/etiología , Anciano , Anciano de 80 o más Años , Bacterias/clasificación , Bacterias/genética , Esófago de Barrett/complicaciones , Esófago de Barrett/patología , Biodiversidad , Susceptibilidad a Enfermedades , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/etiología , Femenino , Mucosa Gástrica/metabolismo , Humanos , Incidencia , Masculino , Metagenoma , Microvellosidades/microbiología , Persona de Mediana Edad , Membrana Mucosa/metabolismo , Membrana Mucosa/microbiología , Membrana Mucosa/patología , Filogenia , Carácter Cuantitativo Heredable , Factores de Riesgo , Estómago/microbiología , Relación Cintura-Cadera
16.
Cancer Causes Control ; 26(4): 581-8, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25701246

RESUMEN

PURPOSE: Tobacco causes many adverse health conditions and may alter the upper gastrointestinal (UGI) microbiome. However, the few studies that studied the association between tobacco use and the microbiome were small and underpowered. Therefore, we investigated the association between tobacco use and the UGI microbiome in Chinese men. METHODS: We included 278 men who underwent esophageal cancer screening in Henan Province, China. Men were categorized as current, former, or never smokers from questionnaire data. UGI tract bacterial cells were characterized using the Human Oral Microbial Identification Microarray. Counts of unique bacterial species and genera estimated alpha diversity. For beta diversity, principal coordinate (PCoA) vectors were generated from an unweighted UniFrac distance matrix. Polytomous logistic regression models were used for most analyses. RESULTS: Of the 278 men in this study, 46.8% were current smokers and 12.6% were former smokers. Current smokers tended to have increased alpha diversity (mean 42.3 species) compared to never smokers (mean 38.9 species). For a 10 species increase, the odds ratio (OR) for current smoking was 1.29 (95% CI 1.04-1.62). Beta diversity was also associated with current smoking. The first two PCoA vectors were strongly associated with current smoking (PCoA1 OR 0.66; 95% CI 0.51-0.87; PCoA2 OR 0.73; 95% CI 0.56-0.95). Furthermore, Dialister invisus and Megasphaera micronuciformis were more commonly detected in current smokers than in never smokers. CONCLUSIONS: Current smoking was associated with both alpha and beta diversity in the UGI tract. Future work should consider how the UGI microbiome is associated with smoking-related diseases.


Asunto(s)
Microbioma Gastrointestinal , Fumar/efectos adversos , Tabaquismo/complicaciones , Pueblo Asiatico , China , Neoplasias Esofágicas/diagnóstico , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Fumar/epidemiología , Cese del Hábito de Fumar , Encuestas y Cuestionarios , Tabaquismo/epidemiología , Tracto Gastrointestinal Superior/microbiología
17.
Biomed Res Int ; 2014: 610767, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24672792

RESUMEN

BACKGROUND: Crohn's disease (CD) may involve any part of the gastrointestinal tract. We assessed the prevalence and features of upper gastrointestinal (UGI) lesions in CD. METHODS: This was a retrospective study that included 138 CD patients that underwent esophagogastroduodenoscopy (EGD). The rate of Crohn's specific endoscopic lesions in the esophagus, stomach, and duodenum was assessed, and immunohistochemical analysis was performed. Changes in the UGI lesions were assessed in those who had two or more EGD. RESULTS: Of 138 patients, 51.3% had Crohn's specific UGI lesions. The rates of Crohn's specific lesion in the esophagus, upper-to-middle stomach, lower stomach, duodenal bulb, and 2nd portion of the duodenum were 6.5%, 47.8%, 24.6%, 31.9%, and 18.1%, respectively. Granulomas were detected in 6.1%, 25.0%, and 11.4% in the upper-to-middle stomach, lower stomach, and duodenal bulb, respectively, but none in the esophagus and 2nd portion of the duodenum. Thirty-seven were analyzed for Helicobacter pylori and 4 were positive (10.8%). Improvements of UGI lesions were seen in 14 out of 49 (28.5%) and were unchanged in 59.2% and worsened in 12.2%. CONCLUSIONS: The prevalence of Crohn's specific UGI lesions was common in our case series, and immunohistochemical studies suggested that the majority was unrelated to Helicobacter pylori infection. Worsening of UGI lesions over the course was rare.


Asunto(s)
Enfermedad de Crohn/patología , Endoscopía del Sistema Digestivo , Tracto Gastrointestinal Superior/patología , Adolescente , Adulto , Anciano , Niño , Enfermedad de Crohn/complicaciones , Enfermedad de Crohn/epidemiología , Enfermedad de Crohn/microbiología , Femenino , Granuloma/patología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/patología , Helicobacter pylori/fisiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Tracto Gastrointestinal Superior/microbiología , Adulto Joven
18.
Appl Environ Microbiol ; 79(23): 7264-72, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24038702

RESUMEN

Several dietary ingredients may affect the bacterial community structure and metabolism in the porcine gut and may therefore influence animals' health and performance. This study investigated the effects of cereal source and calcium-phosphorus (CaP) level in the diet on bacterial microbiota and metabolites, nutrient intake, and gut environment in weaned pigs. Pigs (n=8/treatment) were fed wheat-barley- or corn-based diets with an adequate or high CaP level for 14 days. Effects on microbiota in the stomach, ileum, and midcolon were assessed using quantitative PCR. Data showed that Enterobacteriaceae, Campylobacter spp., and Helicobacter spp., which all contain highly immune reactive lipopolysaccharide (LPS), were abundant at all gut sites. Diet effects on bacteria and metabolites were moderate and occurred mainly in the upper gut, whereas no effects on bacteria, fermentation products, and LPS could be observed in the colon. Differences in carbohydrate intake with corn versus wheat-barley diets selectively stimulated Bifidobacterium in the stomach and ileum. There was a growth advantage for a few bacterial groups in the stomach and ileum of pigs fed the high versus adequate CaP level (i.e., gastric Enterobacteriaceae and ileal Enterococcus, Bacteroides-Prevotella-Porphyromonas, and Campylobacter). Interestingly, gastrointestinal pH was not affected by dietary CaP level. The present findings demonstrate the stability of the bacterial community and gut environment toward dietary changes even in young pigs. The results on stimulation of gastric and ileal Bifidobacterium by corn diets may be employed in nutritional strategies to support gut health after weaning.


Asunto(s)
Biota , Calcio de la Dieta/análisis , Dieta/métodos , Grano Comestible/química , Fósforo/análisis , Porcinos/microbiología , Tracto Gastrointestinal Superior/microbiología , Animales , Hordeum/química , Reacción en Cadena en Tiempo Real de la Polimerasa , Triticum/química , Zea mays/química
20.
Best Pract Res Clin Gastroenterol ; 26(2): 163-72, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22542154

RESUMEN

Low-dose aspirin has been shown to increase the risk of upper gastrointestinal tract injury. Risk factors in upper gastrointestinal complications in low-dose aspirin users are less well defined than in other NSAID users, and there are enough intrinsic differences in the two agents to discuss them separately. In particularly, the role of Helicobacter pylori and the benefit of its eradication in decreasing the risk of upper gastrointestinal tract injury in low-dose ASA users remains controversial. Various consensus groups have recommended H. pylori testing and eradication in low-dose ASA users with a prior history of peptic ulcer or ulcer bleeding. The basis of this recommendation is derived from a limited, albeit expanding evidence on the role of H. pylori in upper gastrointestinal tract injury in low-dose ASA users and on the effectiveness of H. pylori eradication in reducing the risk of complications such as rebleeding in high-risk patients.


Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Aspirina/administración & dosificación , Enfermedades Gastrointestinales/inducido químicamente , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Antiinflamatorios no Esteroideos/efectos adversos , Aspirina/efectos adversos , Ácido Gástrico/metabolismo , Enfermedades Gastrointestinales/microbiología , Enfermedades Gastrointestinales/prevención & control , Hemorragia Gastrointestinal/microbiología , Hemorragia Gastrointestinal/prevención & control , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Úlcera Péptica/complicaciones , Úlcera Péptica/prevención & control , Prevención Secundaria , Tracto Gastrointestinal Superior/efectos de los fármacos , Tracto Gastrointestinal Superior/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...